Vestnik dermatologii i venerologiiVestnik dermatologii i venerologiiВестник дерматологии и венерологии0042-46092313-6294Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov1684410.25208/vdv16844REVIEWSОБЗОР ЛИТЕРАТУРЫReview ArticleCytokine profile of the cervical mucosa of HIV-infected women with papillomavirus infectionЦитокиновый профиль слизистой оболочки шейки матки при папилломавирусной инфекции у ВИЧ-инфицированных женщинhttps://orcid.org/0000-0002-3123-83599107-4118VyalykhIvan V.ВялыхИван Владимирович
Russian Federation

Cand. Sci. (Veterinary)

к.ветеринар.н.

vyalykhivan@yandex.ruhttps://orcid.org/0000-0003-4280-283X7758-6050MishchenkoVladimir A.МищенкоВладимир Алексеевич
Russian Federation
mischenko_va@niivirom.ruVirome Federal Scientific Research Institute of Viral InfectionsФедеральный научно-исследовательский институт вирусных инфекций «Виром»1504202510062025101248540111202403042025Copyright ©; 2025, Vyalykh I.V., Mishchenko V.A.Copyright ©; 2025, Вялых И.В., Мищенко В.А.2025Vyalykh I.V., Mishchenko V.A.Вялых И.В., Мищенко В.А.https://creativecommons.org/licenses/by-nc/4.0https://vestnikdv.ru/jour/article/view/16844

Human papillomavirus is recognized as the main etiologic agent of cervical cancer. Among women with HIV, human papillomavirus infection leads to the development of cervical intraepithelial neoplasia and cancer 3–4 times more often compared with HIV-negative women, despite effective combination antiretroviral therapy. The host immune response is critical in determining the course of infection, and cytokines and chemokines play an important role in protection against HPV by influencing viral replication and modulating the immune response. An analysis of data on studies of the level of cytokines and chemokines in samples of biopsy material and scrapings of the cervix and cervical canal in women with co-infection with HIV and HPV of reproductive age 18 years and older is presented. Data on the cytokine profiles of interferon gamma (IFN-γ), interleukin-10 (IL-10), tumor necrosis factor (TNF), interleukin-6 (IL-6) and macrophage inflammatory protein (MIP) are presented. Knowledge of immunological mechanisms and their influence on HPV infection in HIV-positive women can help in understanding the natural history of infection, improving diagnosis and developing effective methods of prevention and treatment to prevent progression of the disease.

Вирус папилломы человека (ВПЧ) признан основным этиологическим агентом рака шейки матки. Среди женщин с ВИЧ папилломавирусная инфекция приводит к развитию цервикальной интраэпителиальной неоплазии (ЦИН) и рака в 3–4 раза чаще по сравнению с ВИЧ-отрицательными, несмотря на эффективную комбинированную антиретровирусную терапию. Иммунный ответ организма-хозяина имеет решающее значение для определения течения инфекции, а цитокины и хемокины играют важную роль в защите от ВПЧ, влияя на репликацию вируса и модуляцию иммунного ответа. В данном обзоре приведен анализ уровня цитокинов и хемокинов в пробах биопсийного материала, соскобов шейки матки и цервикального канала у женщин с сочетанной инфекцией ВИЧ и ВПЧ в репродуктивном возрасте от 18 лет и старше. Показаны особенности цитокинового профиля интерферона гамма (IFN-γ), интерлейкина-10 (IL- 10), фактора некроза опухоли (TNF), интерлейкина-6 (IL-6) и воспалительного белка макрофагов (MIP). Знания об иммунологических механизмах и их влиянии на инфицирование ВПЧ у женщин, живущих с ВИЧ, могут помочь в понимании естественного течения инфекции, совершенствовании диагностики и разработке эффективных методов профилактики и лечения для предотвращения прогрессирования заболевания.

HIV infectionhuman papillomavirus infectioncervical cancerchemokinescytokinesВИЧ-инфекцияпапилломавирусная инфекциярак шейки маткихемокиныцитокиныThe work was carried out within the framework of the research work “Study of the effectiveness of the cellular immune response in HIV-positive individuals infected with the human papillomavirus” (reg. number in EGISU NIOKTR No. 122040600157-0) of the industry research program of RospotrebnadzorРабота выполнена в рамках научно-исследовательской работы «Изучение эффективности клеточного иммунного ответа у ВИЧ-позитивных лиц, инфицированных вирусом папилломы человека» (рег. номер в ЕГИСУ НИОКТР 122040600157-0) отраслевой научно-исследовательской программы РоспотребнадзораInternational Agency for Research on Cancer: Global Cancer Observatory. URL: https://gco.iarc.fr/en (accessed: 22.06.2024).Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–1953. doi: 10.1002/ijc.31937Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer. 2011;128(4):927–935. doi: 10.1002/ijc.25396Kriek JM, Jaumdally SZ, Masson L, Little F, Mbulawa Z, Gumbi PP, et al. Female genital tract inflammation, HIV co-infection and persistent mucosal Human Papillomavirus (HPV) infections. Virology. 2016;493:247–254. doi: 10.1016/j.virol.2016.03.022Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis. 2009;199(7):936–944. doi: 10.1086/597309IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1–441.Arbyn M, Tommasino M, Depuydt C, Dillner J. Are 20 human papillomavirus types causing cervical cancer? J Pathol. 2014;234(4):431–435. doi: 10.1002/path.4424Rositch AF, Koshiol J, Hudgens MG, Razzaghi H, Backes DM, Pimenta JM, et al. Patterns of persistent genital human papillomavirus infection among women worldwide: A literature review and meta-analysis. Int J Cancer. 2013;133(6):1271–1285. doi: 10.1002/ijc.27828Кедрова А.Г., Подистов Ю.И., Кузнецов В.В., Брюзгин В.В., Козаченко В.П., Никоголян С.О. Роль противовирусной терапии в комплексном лечении больных эпителиальными дисплазиями и преинвазивным раком шейки матки. Гинекология. 2005;7(3):170–1730. [Kedrova AG, Podistov YuI, Kuznecov VV, Bryuzgin VV, Kozachenko VP, Nikogolyan SO. Rol’ protivovirusnoj terapii v kompleksnom lechenii bol’nyh epitelial’nymi displaziyami i preinvazivnym rakom shejki matki. Gynecology. 2005;7(3):170–1730. (In Russ.)]Stelzle D, Tanaka LF, Lee KK, Ibrahim Khalil A, Baussano I, Shah ASV, et al. Estimates of the global burden of cervical cancer associated with HIV. Lancet Glob Health. 2021;9(2):e161–e169. doi: 10.1016/S2214-109X(20)30459-9Дианова Т.В., Свердлова Е.С. Возможные пути профилактики рака шейки матки у ВИЧ-инфицированных женщин. Сибирский медицинский журнал. 2010;6:113–115. [Dianova TV, Sverdlova ES. Possible ways of prevention of cervical cancer in HIV-infected women. Sibirskij medicinskij zhurnal. 2010;6:113–115. (In Russ.)]Свердлова Е.С., Дианова Т.В. Особенности папилломавирусной инфекции у ВИЧ-инфицированных женщин. Эпидемиология и инфекционные болезни. 2012;17(4):9–11. [Sverdlova ES, Dianova TV. Features of papillomavirus infection in HIV-infected women. Epidemiology and Infectious Diseases. 2012;17(4):9–11. (In Russ.)] doi: 10.17816/EID40631Lekoane KMB., Kuupiel D, Mashamba-Thompson TP, Ginindza TG. The interplay of HIV and human papillomavirus-related cancers in sub-Saharan Africa: Scoping review. Syst Rev. 2020;9(1):88. doi: 10.1186/s13643-020-01354-1Kelly H, Weiss HA, Benavente Y, de Sanjose S, Mayaud P, et al. Association of anti-retroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis. Lancet HIV. 2018;5(1):e45–e58. doi: 10.1016/S2352-3018(17)30149-2Аутеншлюс А.И., Лыков А.П., Шкунов А.Н., Вараксин Н.А., Пустошилова Н.М., Морозов В.Д., и др. Оценка про- и противовоспалительных факторов иммунитета у женщин с онкологической патологией и дисплазией генитальной сферы. Цитокины и воспаление. 2008;7(2):18–22. [Autenshlius AI, Lykov АP, Shkunov AN, Varaksin NA, Pustoshilova NM, Morozov VD, et al. Evaluation of the inflammatory and antiinflammatory factors of immunity in women with genital cancer and epithelial dysplasia. Cytokines and Inflammation. 2008:7(2):18–22. (In Russ.)]Хмельницкий О.К. Цитологическая и гистологическая диагностика заболеваний шейки и тела матки. СПб.; 2000. 151 с. [Hmelnickij OK. Citologicheskaya i gistologicheskaya diagnostika zabolevanij shejki i tela matki. Saint Petesburg; 2000. 151 p. (In Russ.)]Прилепская В.Н., Роговская С.И., Кондриков Н.И., Сухих Г.Т. Папилломавирусная инфекция: диагностика, лечение, профилактика: пособие для врачей. М.: МЕДпресс-информ; 2007. 32 с. [Prilepskaya VN, Rogovskaya SI, Kondrikov NI, Suhih GT. Papillomavirusnaya infekciya: diagnostika, lechenie, profilaktika: Posobie dlya vrachej. Moscow: MEDpress-inform; 2007. 32 p. (In Russ.)]Liu G, Sharma M, Tan N, Barnabas RV. HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer. AIDS. 2018;32(6):795–808. doi: 10.1097/QAD.0000000000001765Karim S, Souho T, Benlemlih M, Bennani B. Cervical cancer induction enhancement potential of chlamydia trachomatis: A systematic review. Curr Microbiol. 2018;75(12):1667–1674. doi: 10.1007/s00284-018-1439-7zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2(5):342–350. doi: 10.1038/nrc798Lin W, Niu Z, Zhang H, Kong Y, Wang Z, Yang X, et al. Imbalance of Th1/Th2 and Th17/Treg during the development of uterine cervical cancer. Int J Clin Exp Pathol. 2019;12(9):3604–3612.Fernandes JV, De Medeiros Fernandes TA, De Azevedo JC, Cobucci RN, DE Carvalho MG, Andrade VS, et al. Link between chronic inflammation and human papillomavirus–induced carcinogenesis (Review). Oncol Lett. 2015;9(3):1015–1026. doi: 10.3892/ol.2015.2884Olaitan A, Johnson MA, Reid WM, Poulter LW. Changes to the cytokine microenvironment in the genital tract mucosa of HIV+ women. Clin Exp Immunol. 1998;112(1):100–104. doi: 10.1046/j.1365-2249.1998.00561.xBerti FCB, Pereira APL, Cebinelli GCM, Trugilo KP, Brajão de Oliveira K. The role of interleukin 10 in human papilloma virus infection and progression to cervical carcinoma. Cytokine Growth Factor Rev. 2017;34:1–13. doi: 10.1016/j.cytogfr.2017.03.002Houlihan CF, Larke NL, Watson-Jones D, Smith-McCune KK, Shiboski S, Gravitt PE, et al. Human papillomavirus infection and increased risk of HIV acquisition. A systematic review and meta-analysis. AIDS. 2012;26(17):2211–2222. doi: 10.1097/QAD.0b013e328358d908Kobayashi A, Greenblatt RM, Anastos K, Minkoff H, Massad LS, Young M, et al. Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res. 2004;64(18):6766–6774. doi: 10.1158/0008-5472.CAN-04-1091Nicol AF, Fernandes AT, Grinsztejn B, Russomano F, E Silva JR, Tristão A, et al. Distribution of immune cell subsets and cytokine–producing cells in the uterine cervix of human papillomavirus (HPV)-infected women: Influence of HIV-1 coinfection. Diagn Mol Pathol. 2005;14(1):39–47. doi: 10.1097/01.pas.0000143309.81183.6cFernandes AP, Gonçalves MA, Duarte G, Cunha FQ, Simões RT, Donadi EA. HPV16, HPV18, and HIV infection may influence cervical cytokine intralesional levels. Virology. 2005;334(2):294–298. doi: 10.1016/j.virol.2005.01.029Behbahani H, Walther-Jallow L, Klareskog E, Baum L, French AL, Patterson BK, et al. Proinflammatory and type 1 cytokine expression in cervical mucosa during HIV-1 and human papillomavirus infection. J Acquir Immune Defic Syndr. 2007;45(1):9–19. doi: 10.1097/QAI.0b013e3180415da7Buckley N, Huber A, Lo Y, Castle PE, Kemal K, Burk RD, et al. Association of high-risk human papillomavirus with genital tract mucosal immune factors in HIV-infected women. Am J Reprod Immunol. 2016;75(2):146–154. doi: 10.1111/aji.12461Guha D, Chatterjee R. Cytokine levels in HIV infected and uninfected Indian women: Correlation with other STAs. Exp Mol Pathol. 2009;86(1):65–68. doi: 10.1016/j.yexmp.2008.10.001Kriek JM, Jaumdally SZ, Masson L, Little F, Mbulawa Z, Gumbi PP, et al. Female genital tract inflammation, HIV co-infection and persistent mucosal Human Papillomavirus (HPV) infections. Virology. 2016;493:247–254. doi: 10.1016/j.virol.2016.03.022Nicol AF, Nuovo GJ, Wang Y, Grinsztejn B, Tristão A, Russomano F, et al. In situ detection of SOCS and cytokine expression in the uterine cervix from HIV/HPV coinfected women. Exp Mol Pathol. 2006;81(1):42–47. doi: 10.1016/j.yexmp.2006.01.002Todoric J, Antonucci L, Karin M. Targeting inflammation in cancer prevention and therapy. Cancer Prev Res (Phila). 2016;9(12):895–905. doi: 10.1158/1940-6207.CAPR-16-0209Song SH, Lee JK, Lee NW, Saw HS, Kang JS, Lee KW. Interferon-gamma (IFN-gamma): A possible prognostic marker for clearance of high–risk human papillomavirus (HPV). Gynecol Oncol. 2008;108(3):543–548. doi: 10.1016/j.ygyno.2007.11.006Peghini BC, Abdalla DR, Barcelos AC, Teodoro Ld, Murta EF, Michelin MA. Local cytokine profiles of patients with cervical intraepithelial and invasive neoplasia. Hum Immunol. 2012;73(9):920–926. doi: 10.1016/j.humimm.2012.06.003Kobayashi A, Weinberg V, Darragh T, Smith-McCune K. Evolving immunosuppressive microenvironment during human cervical carcinogenesis. Mucosal Immunol. 2008;1(5):412–420. doi: 10.1038/mi.2008.33Wang Y, Yang J, Huang J, Tian Z. Tumor necrosis factor-α polymorphisms and cervical cancer: Evidence from a meta-analysis. Gynecol Obstetc Invest. 2020;85(2):153–158. doi: 10.1159/000502955Li H, Chi X, Li R, Ouyang J, Chen Y. HIV-1-infected cell-derived exosomes promote the growth and progression of cervical cancer. Int J Biol Sci. 2019;15(11):2438–2447. doi: 10.7150/ijbs.38146Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol. 2018;18(12):773–789. doi: 10.1038/s41577-018-0066-7